

CORPORATE NEWS

MeVis Medical Solutions AG Caroline-Herschel-Strasse 1 28359 Bremen Germany

Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: ir@mevis.de

MeVis publishes figures for the short fiscal year 2016 and guidance for 2017

Operational stability at a high level

- Revenues with € 12.1 m at the level of previous year
- Earnings before interest an taxes (EBIT) of €3.9 m (compared with €4.5 m in twelve months in 2015)
- Net income of €3.4 m (compared with €6.7 m in twelve months in 2015)
- Guidance for 2017:
 - Slight increase in revenues to €16.5 m to €17.0 m
 - Stable EBIT of €4.5 m to €5.0 m

Bremen, January 23, 2017 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its figures for the short fiscal year 2016, with the reporting period January 1 to September 30, 2016.

At € 12.1 m, revenues in 2016 were almost exactly 9/12 of previous year's revenues of € 16.0 m, which were generated in twelve months. The business with Hologic, which represents the Digital Mammography segment, increased slightly in importance, contributing 79 % to revenues. As a result the revenue share of the Other Diagnostics segment declined slightly from 22 % to 21 %.

The share of the license business fell marginally from 48 % of the total revenues in 2015 to 46 % in 2016; In return, the share of the maintenance business increased slightly from 44 % to 45 %. The share of services could be increased from 8 % to 9 % of sales.

Staff costs remained stable at € 5.5 m in nine months of 2016, compared with €7.4 m in twelve months of 2015. Other operating expenses as well as depreciation have fallen significantly.

This results in an EBIT (earnings before interest and taxes) of € 3.9 compared to € 4.5 million in twelve months in 2015, corresponding to an increase in the EBIT margin from 28 % to 32 %.

The financial result decreased year-on-year to € -0.5 m, mainly due to the deterioration in the result from exchange rate differences.

Due to the fiscal unity no income taxes were incurred in the short fiscal year 2016. Thus, after-tax earnings amounted to ≤ 3.4 m in the reporting period (previous year: ≤ 6.7 m), corresponding to undiluted earnings per share of ≤ 1.88 (previous year: ≤ 3.76)

"2016 was also a very successful year for us economically." said Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG." He added: "However, for 2017 we expect a decline of the ongoing business from new license and maintenance contracts with our existing customers." Mr. Kirchhoff, CEO of MeVis Medical Solutions AG, said: "We believe that we can more than compensate this decline in the license and maintenance business through a significant increase in development support for Hologic for the development of its own software and the one-time effect from the sale of extensive software user rights for our prototyping platform MeVisLab to Varian Medical Systems." Dr. Robert Hannemann added: "For 2017, we expect an increase in revenues to € 16.5 m to € 17.0 m, as well as a stable EBIT between € 4.5 m and € 5.0 m."

The interim financial statement for the first quarter 2017 will be published on February 21, 2017.

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.